-
Article
Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study
Since the publication of this paper, the authors noticed an error in Fig. 1. The X-axis on all the figure panels should read ‘Time (years)’, not ‘Time (months)’. The corrected Fig. 1 is shown below.
-
Article
Open AccessChemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study
An increasing number and proportion of cancer patients with apparently localised disease are treated with chemotherapy and radiation therapy in contemporary oncology practice. In a pilot study of radiation-ind...
-
Article
Open AccessPhase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group
Patients with metastatic endometrial carcinoma have a poor prognosis and PIK3CA mutations and amplifications are common in these cancers. This study evaluated the efficacy and safety of the pure PI3K inhibitor...
-
Chapter
Gynecological Carcinosarcomas
Carcinosarcomas (also known as malignant mixed müllerian tumors) are rare and highly aggressive epithelial malignancies that contain both malignant sarcomatous a...
-
Article
L’organisation française en réseau de soins pour la prise en charge des sarcomes
Les sarcomes sont des cancers rares et hétérogènes, dont la prise en charge est complexe et non optimale pour la majorité des patients. Les trois éléments clés de la prise en charge sont l’obtention d’un diagn...
-
Article
Expertise cancérologique en Europe : c’est possible !
-
Article
Open AccessA dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic activity on both pericytes and endothelial cells.
-
Article
Open AccessA phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
Soft tissue sarcomas (STS) are rare tumours for which treatment options are limited in the advanced setting. Histone deacetylase inhibitors have shown activity in preclinical models of STS.
-
Article
Open AccessEverolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
Patients with recurrent/metastatic endometrial cancer that progresses after chemotherapy have limited treatment options and poor outcomes. Preclinical data suggest the oral mammalian target of rapamycin inhibi...
-
Article
Open AccessOpen-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group
Although most patients with advanced gynaecologic malignancies respond to first-line treatment with platinum-taxane doublets, a significant proportion of patients relapse. Combining targeted agents that have n...
-
Chapter and Conference Paper
Anti-angiogéniques en première ligne du cancer du sein métastatique
Ce chapitre présente les données des études pivots de phase III spécifiques à l’association Avastin® + taxane (E2100, AVADO), d’une étude de phase III évaluant différentes association Avastin® + chimiothérapie...
-
Article
Traitements médicamenteux des métastases cérébrales des cancers du sein HER2+
Breast cancer is the second leading cause of brain metastases. In patients with HER2-positive breast cancer, the incidence of brainmetastases is 40%. Although the arrival of anti-HER2 therapies has meant bette...
-
Chapter and Conference Paper
Anti-HER-2 et hormonothérapies dans la prise en charge des cancers du sein: Indications
En cancérologie, le concept de » facteur prédictif thérapeutique « est issu de la connaissance d’une part de l’effet positif de l’hormonothérapie sur certains cancers du sein et d’autre part des récepteurs hor...
-
Article
Thérapies ciblées dans le traitement des carcinomes de l’ovaire
Despite the improvement in surgical management for ovarian carcinoma, it remains the most aggressive gynaecologic cancer with the ability to kill patients. Finding new treatments that can improve survival rate...
-
Chapter
Thérapeutiques du cancer de l’ovaire
Le but du traitement chirurgical du cancer épithélial de l’ovaire est de réaliser une stadification anatomique précise et une réduction tumorale optimale.
-
Article
Open AccessIdentification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
Imatinib induces responses and disease stabilisations in non-resectable patients with aggressive fibromatosis (AF). The precise target of imatinib in AF and predictive factors for response to treatment are unk...
-
Article
Open AccessA prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region
Preliminary data indicate that the molecular epidemiology of localised gastrointestinal stromal tumour (GIST) may be different from that of advanced GIST. We sought to investigate the molecular epidemiology of...
-
Chapter
Que décider après l’apparition d’un échappement aux anti-angiogéniques actuels prescrits aux cancers du sein métastatiques ?
Dans le cancer du sein, l’apparition de métastases est signe d’incurabilité et relève d’un traitement médical dont deux modalités, l’hormonothérapie et la chimiothérapie, sont utilisées depuis des décennies et...
-
Chapter
Rare Ovarian Cancers
Tumours of the ovary represent about 30% of all cancers of the female genital system. Ovarian cancer is the fifth leading cause of death from cancer in women and the leading cause of death from gynaecological ...
-
Chapter
Tumeurs stromales gastro-intestinales (GIST)
Les tumeurs stromales gastro-intestinales (GIST) n’étaient pas reconnues comme des entités cliniques distinctes en 1998, bien que plusieurs équipes d’anatomopathologistes aient rapporté d...
